|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | Groupe Oncologie Radiotherapie Tete et Cou |
|---|---|
| Collaborator: |
Sanofi-Aventis |
| Information provided by: | Groupe Oncologie Radiotherapie Tete et Cou |
| ClinicalTrials.gov Identifier: | NCT00169182 |
Purpose
The purpose of the study is to compare two regimen of chemotherapy used as first treatment for patients with larynx or hypopharynx tumors that would be treated with total laryngectomy. The standard treatment is a combination of 2 drugs (Cisplatin and 5FU). The aim of the study is to evaluate the potential benefit of the addition of a third drug (Docetaxel) in the chemotherapy regimen. Patients will receive 3 cycles of chemotherapy. Responders to the induction treatment are treated with radiation with a purpose of larynx preservation. Non responders patients will be treated with total laryngectomy.
| Condition | Intervention | Phase |
|---|---|---|
|
Larynx Cancer Hypopharynx Cancer |
Drug: DOCETAXEL |
Phase III |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Randomized Study Comparing Induction Chemotherapy With Docetaxel, Cisplatin, 5FU Versus Cisplatin, 5 FU in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma |
| Estimated Enrollment: | 220 |
| Study Start Date: | December 2000 |
The purpose of the study is to compare two regimen of induction chemotherapy for patients with T3 and T4 larynx or hypopharynx carcinoma that would be treated with total laryngectomy. The aim of the study is to compare the standard regimen (Cisplatin + 5FU) versus the TPF regimen (Taxotere + Cisplatin + 5FU). Responders to the induction treatment are treated with radiation with a purpose of larynx preservation. Non responders patients will be treated with total laryngectomy followed by postoperative radiation.
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations More Information
| ClinicalTrials.gov Identifier: | NCT00169182 History of Changes |
| Other Study ID Numbers: | GORTEC 2000-01 |
| Study First Received: | September 9, 2005 |
| Last Updated: | September 9, 2005 |
| Health Authority: | France: Afssaps - French Health Products Safety Agency |
|
Larynx cancer Hypopharynx cancer Chemotherapy Randomized trial Larynx preservation |
|
Carcinoma Laryngeal Neoplasms Laryngeal Diseases Hypopharyngeal Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Otorhinolaryngologic Neoplasms Head and Neck Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms |
Otorhinolaryngologic Diseases Pharyngeal Neoplasms Pharyngeal Diseases Stomatognathic Diseases Docetaxel Cisplatin Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Radiation-Sensitizing Agents Physiological Effects of Drugs |
